Shares of Merck and Pfizer are way down from their previous peaks. Merck's lead drug, Keytruda, grew sales by 19% last year, but its era of patent-protected exclusivity is approaching its end.

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

Merck & Co has said building its cardiovascular medicines business is central to its strategy to manage the loss of patent protection of cancer juggernaut Keytruda in five years, and new studies ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

inactivated Vaqta (Merck) 12 mo at 37 °C Manufacturer Hepatitis B immune globulin (human) Hyperhep B S/D (Bayer) Cumulative exposure for 7 days Manufacturer Hepatitis B vaccine (recombinant ...

After hours: 7:59:57 p.m. EST Loading Chart for MRK ...

Protein concentration was measured with a Bio-Rad protein assay (Biorad, München, Germany). Proteins were separated by 4%–12% sodium dodecyl sulfate/polyacrylamide gel electrophoresis (NuPAGE, ...

4307.T Nomura Research Institute, Ltd.